( en | de | ru )

 

Disambiguation of "Saez-Rodriguez, Julio"

Author of the publication

copydeleteadd this publication to your clipboard
Efficient randomization of biological networks while preserving functional characterization of individual nodes.

, , , , , and . BMC Bioinform., (2016)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Julio Sáez Rodríguez

Julio Rodriguez

Julio Rodríguez Navarro

Julio Rodríguez Contreras

Carlos Julio Cortés Rodríguez

 

Other publications of authors with the same name

Assessment of network module identification across complex diseases, , , , , , , , , and 168 other author(s). Nature Methods, 16 (9): 843--852 (2019)Inferring causal molecular networks: empirical assessment through a community-based effort, , , , , , , , , and 163 other author(s). Nature Methods, 13 (4): 310--318 (Feb 22, 2016)A Landscape of Pharmacogenomic Interactions in Cancer, , , , , , , , , and 29 other author(s). Cell, 166 (3): 740 - 754 (2016)Integrating literature-constrained and data-driven inference of signalling networks., , , , and . Bioinform., 28 (18): 2311-2317 (2012)Network based elucidation of drug response: from modulators to targets., , and . BMC Syst. Biol., (2013)MEIGO: an open-source software suite based on metaheuristics for global optimization in systems biology and bioinformatics., , , , , and . CoRR, (2013)Reusability and composability in process description maps: RAS-RAF-MEK-ERK signalling., , , , , and . Briefings Bioinform., (2021)SysMod: the ISCB community for data-driven computational modelling and multi-scale analysis of biological systems., , , , , , , , , and 2 other author(s). Bioinform., 37 (21): 3702-3706 (2021)GDSCTools for mining pharmacogenomic interactions in cancer., , , , , , and . Bioinform., 34 (7): 1226-1228 (2018)Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity., , , , , , , , , and 1 other author(s). PLoS Comput. Biol., (2022)